Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (January 2021)
22 slides from Cantargia Ab's investor presentation, Jan 19, 2021
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO JANUARY 2021
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: I. Introduction
I. INTRODUCTION
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value Discovery Preclinical Project phase phase Phase I Phase II Phase III Commercial phase CAN04 ➢ Potentially more effective treatment against novel Pancreatic cancer Chemo combinations target in clinically validated Non-small cell lung cancer Chemo
Slide 5: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT Current owners (30 Dec 2020) • Positive interim data set - response rates higher than historical control PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS Swedbank Robur Funds 9.7% • Target IL1RAP found on most s
Slide 6: II. Lead antibody CAN04
II. LEAD ANTIBODY CAN04
Slide 7: CAN04 – Superior IL-1 blocking approach
CAN04 – Superior IL-1 blocking approach Company Compound IL-1α IL-1β ADCC Indication/dev phase Cantargia CAN04 ++ ++ ++ • Pancreatic cancer, NSCLC phase IIa Xbiotech/ Xilonix • Autoimmunity, dermatology ++ – + Janssen • Pancreatic cancer, phase I Novartis Canakinumab • Autoimmunity, registered Gevok
Slide 8: CAN04 – Mechanism of action
CAN04 – Mechanism of action ADCC – Reduced activation Reduced Tumor cell death and infiltration of angiogenesis immunosuppressive cells Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated Fibroblast. NK = Natural Killer. MCP = Monocyte Chemoattractant Protein. MMP = Matrix
Slide 9: Counteracting tumor inflammation (IL-1 pathway) - validated in 10.000 patient study
Counteracting tumor inflammation (IL-1 pathway) - validated in 10.000 patient study Cantos trial (n=10,061) Canakinumab phase iii trials • Canakinumab (Novartis) ADJUVANT NSCLC • 1,500 patients • Reduced lung cancer incidence by 67% and death by 77% (CANOPY-A) • After surgery, no mets, placebo contr
Slide 10: Positive interim data – pancreatic cancer
Positive interim data– pancreatic cancer RECIST 1.1 Patient X CA19-9 Patient X 50 500 RECIST 1.1 (mm) 40 400 CA19-9 (kE/L) 30 300 20 200 10 100 0 0 0 10 20 30 0 10 20 30 Visit Visit RECIST 1.1 Patient Y CA19-9 Patient Y 40 150 RECIST 1.1 (mm) 30 CA19-9 (kE/L) 100 20 50 10 0 0 0 10 20 30 → CAN04 comb
Slide 11: Tumor shrinkage – NSCLC combination
Tumor shrinkage – NSCLC combination → CAN04 in combination with gem/cis in 1st line chemotherapy Patient → 6 of 9 evaluable patients with metastatic non-small cell lung 1 2 3 4 5 6 7 8 9 0 cancer (NSCLC) showed objective response including 1 Percent tumor reduction complete response (67% vs historic
Slide 12: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial Interim Final/ Jun-19 Q3/Q4 update 2020 H1 2021 CANFOUR RESULTS PHASE I – Dose escalation with PHASE IIa – Dosage with assessment of therapeutic effect safety assessment Monotherapy Combination therapy, NSCLC (Dose group X) Recommended phase II dose Combination therapy
Slide 13: Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)
Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020) → Upregulation of both forms of IL-1 in PDX-model as response to Gem/Cis → CAN04 increases efficacy of Pt based chemotherapy regimes → CAN04 counteracts weight loss after chemotherapy SYNERGY WITH CHEMOTHERAPY IN LINE W
Slide 14: III. CAN04 Oncology expansion and next steps
III. CAN04 ONCOLOGY EXPANSION AND NEXT STEPS
Slide 15: IL1RAP in several cancer with high medical need
IL1RAP in several cancer with high medical need IL1RAP % of patients with IL1RAP CANTARGIA • Discovery of IL1RAP on cancer cells Cancer cell surface Stroma FOUNDATION • Antibodies against IL1RAP – antitumor effects 100 • IP on antibody therapy against IL1RAP 90 80 PRIMARY • Non-small cell lung cance
Slide 16: US Phase I clinical trial
US Phase I clinical trial → First patient started → Combination with checkpoint inhibitor in patients no longer responding to PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC, malignant melanoma and bladder cancer (18
Slide 17: CAN04 – Broadening development
CAN04– Broadening development DISCOVERY PRECLINICAL COMMERCIAL PROJECT PHASE PHASE PHASE I PHASE II PHASE III PHASE CAN04 → Basket trial under design Pancreatic cancer Chemo combinations → Strategy to find next step diseases and combination partners Non-small cell lung → NSCLC with docetaxel, TNBC w
Slide 18: IV. Untapped possibilities in autoimmune diseases
IV. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES
Slide 19: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in mouse model → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on s
Slide 20: V. Milestones and summary
V. MILESTONES AND SUMMARY
Slide 21: Cantargia has several near-term value inflection points
Cantargia has several near-term value inflection points Newsflow next 6–9 months CAN04 → Phase IIa combination results PDAC and NSCLC → Next steps combination therapy PDAC and NSCLC → Phase IIa biomarker/biopsy results → Start new clinical trials • FOLFIRINOX combination PDAC • Basket trial NSCLC an
Slide 22: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • Positive interim data set and further phase II milestones during 2020 PLATFORM WITH MANY POTENTIAL THERAPEUTIC AREAS • Cancer and large number of autoimmune/inflammatory diseases VISION OF BECOMING AN IMPORT